Insider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $207,118.36 in Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,223 shares of the company’s stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $9.32, for a total transaction of $207,118.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Adrian Haigh also recently made the following trade(s):

• On Friday, April 19th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.34, for a total transaction of $207,553.48.
• On Wednesday, April 17th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.91, for a total transaction of $220,220.02.
• On Monday, April 15th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $10.30, for a total transaction of $228,886.60.

Fennec Pharmaceuticals Stock Down 1.8 %

FENC opened at $9.07 on Thursday. Fennec Pharmaceuticals Inc has a twelve month low of $6.30 and a twelve month high of $11.92. The company has a 50-day simple moving average of $10.05 and a 200 day simple moving average of $9.42. The stock has a market capitalization of $245.80 million, a price-to-earnings ratio of -14.87 and a beta of 0.38.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.12). The company had revenue of $9.74 million for the quarter, compared to analyst estimates of $9.47 million. Sell-side analysts anticipate that Fennec Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and issued a $16.00 target price on shares of Fennec Pharmaceuticals in a research report on Monday, March 18th. Craig Hallum boosted their target price on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Finally, HC Wainwright boosted their target price on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Thursday, April 4th.

Institutional Investors Weigh In On Fennec Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of FENC. Worth Venture Partners LLC lifted its position in Fennec Pharmaceuticals by 52.7% during the fourth quarter. Worth Venture Partners LLC now owns 141,500 shares of the company’s stock worth $1,588,000 after purchasing an additional 48,864 shares during the period. AIGH Capital Management LLC lifted its holdings in shares of Fennec Pharmaceuticals by 6.9% in the third quarter. AIGH Capital Management LLC now owns 373,526 shares of the company’s stock worth $2,805,000 after acquiring an additional 24,069 shares during the last quarter. Eudaimonia Advisors LLC lifted its holdings in shares of Fennec Pharmaceuticals by 90.8% in the fourth quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company’s stock worth $367,000 after acquiring an additional 15,556 shares during the last quarter. Jump Financial LLC bought a new position in shares of Fennec Pharmaceuticals in the fourth quarter worth about $158,000. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of Fennec Pharmaceuticals in the third quarter worth about $50,000. Institutional investors own 55.51% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.